CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 115 enrolled
Drug / intervention
Placebo (matched to VX-121 suspension) +7 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03768089
NCT03768089Phase 2Completed
CompareCT.gov

A Phase 1/2 Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis

Vertex Pharmaceuticals Incorporated·interventional·Posted Dec 7, 2018·Updated Jul 14, 2022

In Brief

A Phase 2 clinical trial evaluating Placebo (matched to VX-121 suspension), VX-121 (Suspension), and 6 other interventions for Cystic Fibrosis. Completed, enrolled 115 participants across 7 sites in 2 countries.

Detailed Summary

The purpose of this study is to evaluate safety and tolerability of VX-121 in healthy subjects and in subjects with cystic fibrosis (CF).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCystic Fibrosis
CountriesNetherlands, United Kingdom
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedDec 7, 2018
Enrollment StartMar 20, 2018
Primary CompletionMay 3, 2019
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 7.6 years ago

Interventions

Placebo (matched to VX-121 suspension)drug

Placebo matched to VX-121 suspension for oral administration.

VX-121 (Suspension)drug

Suspension for oral administration.

TEZ/IVAdrug

Fixed-dose combination tablet for oral administration.

IVAdrug

Tablet for oral administration.

Placebo (matched to TEZ/IVA)drug

Placebo matched to TEZ/IVA for oral administration.

Placebo (matched to IVA)drug

Placebo matched to IVA for oral administration.

VX-121 (Tablet)drug

Tablet for oral administration.

Placebo (matched to VX-121 tablet)drug

Placebo matched to VX-121 tablet for oral administration.